Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1

E Flemington1, S H Speck

  • 1Division of Tumor Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Journal of Virology
|March 1, 1990
PubMed

Insights

The Epstein-Barr virus (EBV) BZLF1 gene product, ZEBRA, activates its own promoter through novel binding domains. This ZEBRA binding can bypass the need for the ZII domain, initiating the viral lytic cycle.

Area of Science:

  • Virology
  • Molecular Biology
  • Gene Regulation

Background:

  • Epstein-Barr virus (EBV) BZLF1 gene expression triggers the viral lytic cycle in infected lymphocytes.
  • The BZLF1 promoter (Zp) has TPA-responsive elements (ZI and ZII), but its activity is lower in EBV-negative cells.

Purpose of the Study:

  • To investigate the mechanism by which ZEBRA transactivates its own promoter.
  • To identify novel ZEBRA-binding domains and their role in BZLF1 gene regulation.

Main Methods:

  • Transactivation assays in EBV-negative and EBV-positive cell lines.
  • Identification and characterization of ZEBRA-binding sites on the BZLF1 promoter.
  • Analysis of ZEBRA domain homology and binding affinity.

Main Results:

  • ZEBRA directly binds to a novel region on Zp, distinct from ZI and ZII.
  • This region contains two unique transactivation domains: ZIIIA and ZIIIB.
  • ZIIIB exhibits higher binding affinity and no homology to consensus ZEBRA sites.
  • Transactivation is independent of the ZII domain, suggesting ZEBRA binding compensates for its absence.

Conclusions:

  • ZEBRA autoregulation involves direct binding to unique promoter domains.
  • ZEBRA binding can functionally replace the ZII domain, driving BZLF1 transcription.
  • This mechanism supports a model where ZEBRA synthesis commits the virus to the lytic cascade.